Virtual Library

Start Your Search

Min Yu



Author of

  • +

    Lunch & Poster Display session (ID 58)

    • Event: ELCC 2019
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1
    • +

      164P - PD-L1 expression affect the efficacy of pemetrexed maintenance therapy in real-world patients with advanced non-squamous NSCLC (ID 278)

      12:30 - 13:00  |  Author(s): Min Yu

      • Abstract
      • Slides

      Background

      It has been demonstrated that pemetrexed maintenance therapy is an effective and well tolerated option for patients with advanced non-squamous non-small cell lung cancer (NSCLC). This study aimed to investigate the impacts of clinical features, gene status and PD-L1 expression on the efficacy of pemetrexed maintenance therapy in real-world.

      a9ded1e5ce5d75814730bb4caaf49419 Methods

      The clinicopathological characteristics and prognostic data of 102 patients with advanced non-squamous NSCLC who received pemetrexed maintenance therapy between May 2011 and October 2017 were retrospectively analyzed. Kaplan-Meier method with Log-rank test was used for survival analysis. Multivariate Cox regression were used to identify variables associated with median progression free survival (mPFS).

      20c51b5f4e9aeb5334c90ff072e6f928 Results

      102 patients completed 485 cycles of induction chemotherapy and 509 cycles of maintenance chemotherapy, with a mPFS of 11.9 months (95%CI 9.95-13.84). The mPFS of ALK-positive patients was superior to negative patients (18.3 vs. 11.4 months; P = 0.032). Patients with PD-L1 expression ≥50% had significantly prolonged mPFS compared with PD-L1 <50% (17.5 vs. 11.4 months; P = 0.034). Bivariate correlation showed that PFS was significantly positively related to PD-L1 expression (R = 0.359, P = 0.001). No differences were found between EGFR positive and negative patients. The independent beneficial prognostic factors for PFS were age ≥65 years old (HR, 0.328; 95% CI, 0.137-0.787; P = 0.013) and ALK rearrangements (HR, 0.120; 95% CI, 0.027-0.533; P = 0.005).

      fd69c5cf902969e6fb71d043085ddee6 Conclusions

      Pemetrexed has been shown to be efficacious in patients with advanced non-squamous NSCLC. ALK rearrangements and high PD-L1 expression are more likely to have longer PFS of pemetrexed maintenance therapy.

      b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study

      The authors.

      213f68309caaa4ccc14d5f99789640ad Funding

      Has not received any funding.

      682889d0a1d3b50267a69346a750433d Disclosure

      All authors have declared no conflicts of interest.

      cffcb1a185b2d7d5c44e9dc785b6bb25

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.